​

bioAffinity Stock (NASDAQ:BIAF)

RevenueOwnershipFinancialsChart
bioAffinity by TradingView

Previous Close

$3.17

52W Range

$2.80 - $80.70

50D Avg

$6.48

200D Avg

$19.66

Market Cap

$17.59M

Avg Vol (3M)

$3.71M

Beta

-1.11

Div Yield

-

BIAF Company Profile

As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

57

IPO Date

Sep 01, 2022

Website

BIAF Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Other Revenues$4.86K$21.52K-
Health Care, Patient Service$4.97M$516.00K-
Health Care, Other--$19.32K

Fiscal year ends in Dec 24 | Currency in USD

BIAF Financial Summary

Dec 24Dec 23Dec 22
Revenue$9.36M$2.53M$4.80K
Operating Income$9.44M$-7.97M$-4.01M
Net Income$-9.04M$-7.94M$-8.15M
EBITDA-$-7.63M$-5.61M
Basic EPS-$-0.91$-1.81
Diluted EPS-$-0.91$-1.81

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
ARTLArtelo Biosciences, Inc.
WOKWORK Medical Technology Group Ltd. Class A
PBMPsyence Biomedical Ltd.
GTBPGT Biopharma, Inc.
REVBRevelation Biosciences, Inc.
MNDRMobile-health Network Solutions Class A Ordinary Shares
CARMCarisma Therapeutics, Inc.
PTIXProtagenic Therapeutics, Inc.